4D Molecular Therapeutics Temettü

Temettü kriter kontrolleri 0/6

4D Molecular Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-83.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-83.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: FDMT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: FDMT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

4D Molecular Therapeutics Piyasaya Karşı Temettü Getirisi

FDMT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (FDMT)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (FDMT) (3 yıla kadar)	0%

Önemli Temettü: FDMT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, FDMT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: FDMT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: FDMT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

4D Molecular Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

New major risk - Revenue and earnings growth

New major risk - Share price stability

4D Molecular Therapeutics Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4Front Phase 3 Program At 4D-150 Wet AMD Development Day

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Management Changes

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

4D Molecular Therapeutics, Inc. Announces Initial Interim 24-Week Data from the Population Extension Cohort of Its Phase 2 Clinical Trial

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference

First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 9.3% to US$54.75

4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Consensus revenue estimates decrease by 33%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Chief Medical Officer exercised options and sold US$354k worth of stock

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million.

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Price target increased by 9.6% to US$37.00

4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Co-Founder notifies of intention to sell stock

Insufficient new directors

Consensus revenue estimates increase by 96%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC

4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States

4D Molecular Therapeutics, Inc. Announces Executive Changes

Price target decreased by 14% to US$33.50

4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD

Consensus revenue estimates increase by 41%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023

Consensus revenue estimates increase by 163%

4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting

4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target increased by 8.3% to US$41.17

Full year 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

Price target increased by 8.1% to US$38.00

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$85k worth of stock

Price target increased to US$23.80

High number of new directors

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022

High number of new directors

High number of new directors

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations